Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




May
19
Today In Oncology
Providing Culturally Sensitive Palliative Care to Children With Cancer
Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival
Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer Comparison of Agents
FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-Stage SCLC
Half-Matched Family Donors May Improve ASCT Outcomes in Hispanic Patients With ALL
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside